Literature DB >> 6129605

Pharmacological investigations of neurotransmitter involvement in passive avoidance responding: a review and some new results.

G Bammer.   

Abstract

The roles of acetylcholine (ACh), noradrenaline (NA), dopamine (DA) and serotonin (5-HT) in passive avoidance responding are examined by reviewing previous studies of the effects on this task of drugs which alter the functioning of these neurotransmitter systems and also by presenting the results of a new study. This new study includes a number of drugs which do not seem to have been examined before, namely pilocarpine, pempidine, pentolinium, tetrabenazine, desipramine, clonidine, isoprenaline, pimozide, fluoxetine, L-tryptophan, methysergide and cyproheptadine. Because there is large variability in the effects of any one drug or class of drugs on passive avoidance responding, it is difficult to determine the exact involvement of the various neurotransmitter systems. There is also little good evidence that drug effects on performance of the passive avoidance response are caused by drug-induced changes in learning and memory processes or by state-dependent effects. Three other factors which may influence performance of the passive avoidance response-shock sensitivity, the biochemical response to stress and locomotor activity-are discussed and may be responsible for many of the drug-induced changes in passive avoidance responding.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6129605     DOI: 10.1016/0149-7634(82)90041-0

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  28 in total

1.  Effects of the selective M1 muscarinic receptor antagonist dicyclomine on emotional memory.

Authors:  R V Fornari; K M Moreira; M G Oliveira
Journal:  Learn Mem       Date:  2000 Sep-Oct       Impact factor: 2.460

2.  Cholinergic drugs reverse AF64A-induced impairment of passive avoidance learning in rats.

Authors:  N Yamazaki; K Kato; E Kurihara; A Nagaoka
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Evidence for a possible interaction between noradrenergic and serotonergic neurotransmission in the retrieval of a previously learned aversive habit in mice.

Authors:  H J Normile; H J Altman
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 4.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Effects of systemic and intracerebroventricular administration of mecamylamine, a nicotinic cholinergic antagonist, on spatial memory in rats.

Authors:  M W Decker; M J Majchrzak
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Enhancement of the memory of a previously learned aversive habit following pre-test administration of a variety of serotonergic antagonists in mice.

Authors:  H J Altman; H J Normile
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 7.  Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification.

Authors:  M Sarter; J P Bruno; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 8.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

9.  Effects of oxotremorine on inhibitory avoidance behaviour in two inbred strains of mice: interaction with 5-methoxy-NN-dimethyltriptamine.

Authors:  F Pavone; S Fagioli; C Castellano
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Nicotinic systems and cognitive function.

Authors:  E D Levin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.